Last reviewed · How we verify
NCT07466056
Application of Non-inductive Intelligent Physical Sign Monitoring Equipment Based on Flexible Electronic Devices in the Diagnosis and Treatment of Cardiovascular Diseases
trial testing Non-invasive Smart Mattress Monitoring System in Cardiovascular Disease in 1,100 participants. Currently enrolling.
30 September 2027
Quick facts
| Lead sponsor | Beijing Anzhen Hospital |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 1,100 |
| Start date | 1 October 2024 |
| Primary completion | 30 September 2027 |
| Estimated completion | 30 September 2027 |
| Sites | 1 location across China |
Drugs / interventions tested
- Non-invasive Smart Mattress Monitoring System
Conditions studied
- Cardiovascular Disease — all drugs for Cardiovascular Disease →
Sponsor
Beijing Anzhen Hospital
Who can join
Adults 18 to 85, any sex, with Cardiovascular Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This project is a single-center clinical evaluation study designed to validate a non-invasive mattress-based smart monitoring system. The system is intended for installation on standard hospital beds to provide continuous, contact-free monitoring of vital signs, including heart rate, respiration, body temperature, and posture, in patients with cardiovascular diseases. The system will integrate monitoring data with hospital information systems and personal health platforms to support clinical management and remote health monitoring.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07466056
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cardiovascular Disease
Currently open trials in the same condition.
- NCT07238556 — A Novel Digital Tool Physicians Can Use to Prescribe Exercise to Patients With Cardiovascular Disease Risk Factors · NA · recruiting
- NCT07293260 — Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction - Coronary Computed Tomography Angiography Trial · Phase 3 · recruiting
- NCT07497932 — Nutritional Effects in Cardiovascular Surgery · NA · recruiting
- NCT06625073 — Randomized Trial of SGLT2i in Heart Transplant Recipients · Phase 4 · recruiting
- NCT06485700 — Peers and Technology for Adherence, Access, Accountability, and Analytics (PT4A) · NA · recruiting
Other Beijing Anzhen Hospital trials
Trials by the same sponsor.
- NCT07521488 — LLM-Based Intelligent Health Management Assistant in Life-Cycle Health Management of Cardiac Surgery Patients · NA · not yet recruiting
- NCT07470814 — Multidisciplinary Collaborative Care System for Acute Myocardial Infarction Complicated With Cardiogenic Shock · not yet recruiting
- NCT07444372 — Start CPAP Therapy in Obstructive Sleep Apnea Patients After Atrial Fibrillation Ablation · NA · not yet recruiting
- NCT07256197 — PCSK9 Inhibitors in the Treatment of Calcific Aortic Stenosis · Phase 3 · not yet recruiting
- NCT07485101 — Glycemic Targets During CPB in Elderly Diabetes · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07466056 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Beijing Anzhen Hospital
- Last refreshed: 13 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07466056.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing